Advertisement

Advertisement

Neuroendocrine Tumors

Alkylating Agent–Based Treatment in Neuroendocrine Tumors According to MGMT Status

In a French phase II trial (MGMT-NET) reported in the Journal of Clinical Oncology, Walter et al found evidence of activity of alkylating agent–based therapy among patients who have neuroendocrine tumors (NETs) with MGMT-deficient (dMGMT) status. Study Details In the multicenter open-label trial,...

Bladder Cancer
Prostate Cancer
Neuroendocrine Tumors
Immunotherapy

Pembrolizumab Plus Standard Chemotherapy May Benefit Patients With Rare, Aggressive Cancers

Researchers have found that combining the immunotherapy drug pembrolizumab with standard chemotherapy may improve treatment outcomes in patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer, according to a recent study published by Gu et al in Cell Reports Medicine....

Neuroendocrine Tumors
Issues in Oncology

Phase III CABINET Trial: Cabozantinib in Advanced Neuroendocrine Tumors

Cabozantinib may be effective at improving progression-free survival in patients with previously treated neuroendocrine tumors, according to recent findings presented by Chan et al at the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract 1141O) and simultaneously published in The ...

Gastrointestinal Cancer
Neuroendocrine Tumors

Advanced Neuroendocrine Tumors: Adding Lu-177 Dotatate to Standard First-Line Therapy

As reported in The Lancet by Simron Singh, MD, MPH, FRCPC, and colleagues, primary results of the international, multicenter, randomized phase III NETTER-2 study have shown significantly improved progression-free survival with the addition of the radioligand lutetium-177 dotatate (Lu-177 dotatate)...

Neuroendocrine Tumors

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

On April 23, the U.S. Food and Drug Administration (FDA) approved lutetium Lu-177 dotatate (Lutathera) for pediatric patients aged 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut...

Neuroendocrine Tumors

Sunitinib in Metastatic Progressive Pheochromocytomas and Paragangliomas

In a phase II trial (FIRSTMAPPP) reported in The Lancet, Eric Baudin, MD, and colleagues found that the multikinase inhibitor sunitinib was active in patients with metastatic progressive pheochromocytomas and paragangliomas. As stated by the investigators, “No randomized controlled trial has ever...

Neuroendocrine Tumors
Issues in Oncology

UCHL1 Protein: Potential Biomarker and Therapeutic Target in Neuroendocrine Carcinomas and Neuroblastoma?

Investigators have found that the protein UCHL1 may be used as a molecular biomarker for diagnosing patients with highly aggressive neuroendocrine carcinomas and neuroblastoma and predicting and monitoring responses to therapy, according to a study published by Liu et al in Cell Reports Medicine....

gastrointestinal cancer
neuroendocrine tumors

Lorraine A. Chantrill, PhD, MBBS, on Gastrointestinal Neuroendocrine Carcinomas: First-Line Treatment With Nab-Paclitaxel Plus Carboplatin

Lorraine A. Chantrill, PhD, MBBS, of Australia’s Wollongong Hospital, New South Wales, discusses phase II findings on the combination of nab-paclitaxel plus carboplatin as a first-line treatment for patients with gastrointestinal neuroendocrine carcinomas. According to Dr. Chantrill, this regimen appears to be active in these tumors and warrants further evaluation in a phase III trial (Abstract 589).

Neuroendocrine Tumors

NETTER-2: Lu-177 Dotatate for Advanced Gastroenteropancreatic Neuroendocrine Tumors

Results from the first phase III clinical trial evaluating radioligand therapy in the first-line setting demonstrated that treatment with lutetium Lu-177 dotatate significantly improved progression-free survival and objective response rates in patients with high-grade gastroenteropancreatic...

Prostate Cancer
Neuroendocrine Tumors

Novel Blood Test May Help Distinguish Neuroendocrine Prostate Cancer From Other Subtypes

A novel blood test may accurately detect neuroendocrine prostate cancer and differentiate it from castration-resistant prostate adenocarcinoma, according to a recent study published by Franceschini et al in Cancer Discovery. Background Approximately 10% to 15% of patients with metastatic prostate...

Neuroendocrine Tumors

New Guideline Offers Much-Needed Support in the Treatment of Neuroendocrine Tumors

An ASCO guideline has been developed to inform the use of systemic treatments for metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).1 The guideline helps fill a knowledge gap among community oncologists in particular, who typically do not see many of these rare ...

Neuroendocrine Tumors

Cabozantinib for Pretreated Patients With Advanced Neuroendocrine Tumors: CABINET Trial

The Alliance for Clinical Trials in Oncology announced detailed results from CABINET (Alliance A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors. The data were presented by Chan et al at the...

Neuroendocrine Tumors
Pancreatic Cancer

Study Shows Potential of Cabozantinib to Treat Patients With Advanced Neuroendocrine Tumors

An interim analysis of the CABINET trial has shown that the phase III pivotal trial has met its primary endpoint, according to a press release from the Alliance for Clinical Trials in Oncology. Cabozantinib demonstrated statistically significant and clinically meaningful improvements in...

Pancreatic Cancer
Gastrointestinal Cancer
Neuroendocrine Tumors

Second-Line Bevacizumab Plus FOLFIRI for Advanced Gastroenteropancreatic Neuroendocrine Carcinoma

In a French noncomparative phase II trial (PRODIGE 41-BEVANEC) reported in The Lancet Oncology, Walter et al found that the addition of bevacizumab to FOLFIRI (irinotecan, leucovorin, and fluorouracil) did not appear to improve overall survival in the second-line treatment of patients with advanced ...

Lung Cancer
Neuroendocrine Tumors

SBRT for Patients With Primary Lung Neuroendocrine Tumors

Researchers have found that stereotactic body radiotherapy (SBRT) may be an effective treatment for patients with early-stage lung neuroendocrine tumors, according to a new study published by Oliver et al in the International Journal of Radiation Oncology • Biology • Physics. Background Primary...

Neuroendocrine Tumors

Appendectomy With or Without Hemicolectomy for 1- to 2-cm Appendiceal Neuroendocrine Tumors

In a European retrospective cohort study reported in The Lancet Oncology, Nesti et al found evidence that right-sided hemicolectomy is not indicated in patients who had complete resection, via appendectomy, of appendiceal neuroendocrine tumors (NETs) measuring 1 to 2 cm. As stated by the...

Neuroendocrine Tumors

Study Finds That Patients With Neuroendocrine Cancer and Doctors May Agree on Treatment Goals Only Half of the Time

Researchers revealed that patients with neuroendocrine cancer overwhelmingly prioritized quality of life over living longer, according to a new study published by Li et al in JNCCN–Journal of the National Comprehensive Cancer Network.   The researchers surveyed 60 patients with advanced...

Neuroendocrine Tumors

Addition of Capecitabine to Temozolomide in Advanced Pancreatic Neuroendocrine Tumors

As reported in the Journal of Clinical Oncology by Pamela L. Kunz, MD, and colleagues, the phase II ECOG-ACRIN E2211 trial has shown significantly prolonged progression-free survival with the addition of capecitabine to temozolomide in patients with advanced pancreatic neuroendocrine tumors. Study ...

Neuroendocrine Tumors
Gastrointestinal Cancer

Etoposide/Cisplatin vs Irinotecan/Cisplatin in Advanced Digestive System Neuroendocrine Carcinoma

In a Japanese phase III trial (TOPIC-NEC) reported in JAMA Oncology, Morizane et al found no difference in overall survival with etoposide/cisplatin (EP) vs irinotecan/cisplatin (IP) in chemotherapy-naive patients with advanced digestive system neuroendocrine carcinoma. Study Details The open-label ...

Neuroendocrine Tumors

Capecitabine Plus Temozolomide vs Temozolomide Alone in Advanced Pancreatic Neuroendocrine Tumors

In the updated final analysis of the phase II ECOG-ACRIN E2211 trial, patients with advanced pancreatic neuroendocrine tumors experienced a significant improvement in progression-free survival with capecitabine plus temozolomide over temozolomide alone.1 Although the 5-month difference in overall...

neuroendocrine tumors

Mairéad G. McNamara, PhD, MBBCh, on Neuroendocrine Carcinoma: Findings on Liposomal Irinotecan Plus Fluorouracil and Folinic Acid or Docetaxel

Mairéad G. McNamara, PhD, MBBCh, of The Christie NHS Foundation Trust, discusses phase II findings of the NET-02 trial, which explored an unmet need in the second-line treatment of patients with progressive, poorly differentiated extrapulmonary neuroendocrine carcinoma. In the trial, the combination of liposomal irinotecan, fluorouracil, and folinic acid, but not docetaxel, met the primary endpoint of 6-month progression-free survival rate (Abstract 4005).

Neuroendocrine Tumors

Atezolizumab Plus Bevacizumab Shows Activity in Advanced Neuroendocrine Tumors

In a single-institution phase II study reported in JAMA Oncology, Halperin et al found that the combination of atezolizumab and bevacizumab showed activity in treatment of advanced well-differentiated neuroendocrine tumors. As stated by the investigators, “Therapies for patients with advanced...

Neuroendocrine Tumors

Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors: Implications for Current Practice

The rising incidence and prevalence of gastroenteropancreatic endocrine tumors make them the second-most prevalent gastrointestinal cancer.1 Although most of these tumors are relatively slow growing, their histologic grade and differentiation are closely correlated with their clinical behavior.2,3...

Neuroendocrine Tumors

Lu-177 Dotatate Plus Long-Acting Octreotide vs High‑Dose Long-Acting Octreotide in Midgut Neuroendocrine Tumors

As reported in The Lancet Oncology by Jonathan R. Strosberg, MD, of Moffitt Cancer Center, and colleagues, the final overall survival analysis of the phase III NETTER-1 trial has shown an approximately 12-month benefit with the addition of lutetium Lu-177 dotatate to long-acting octreotide in...

Neuroendocrine Tumors

Upfront Peptide Receptor Radionuclide Therapy for Enteropancreatic Neuroendocrine Tumors

In an Italian retrospective cohort study reported in JAMA Network Open, Pusceddu et al found that upfront peptide receptor radionuclide therapy (PRRT) was associated with better progression-free survival vs upfront chemotherapy or targeted therapy in patients with advanced well-differentiated...

Neuroendocrine Tumors

Clinical Score May Assist in Guiding Peptide Receptor Radionuclide Therapy Decisions for Patients With Neuroendocrine Tumors

Peptide receptor radionuclide therapy (PRRT) with lutetium-177 (Lu-177) dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but clinicians have lacked a metric for predicting its benefit on an individual patient basis....

Neuroendocrine Tumors

NETTER-1 Trial: Final Overall Survival Analysis of Lu-177 Dotatate Plus Long-Acting Octreotide vs High-Dose Long-Acting Octreotide for Midgut Neuroendocrine Tumors

As reported in The Lancet Oncology by Jonathan R. Strosberg, MD, and colleagues, the final overall survival analysis of the pivotal phase III NETTER-1 trial has shown an approximate 12-month benefit with the addition of lutetium-177 (Lu-177) dotatate to long-acting octreotide in patients with...

Neuroendocrine Tumors

Expert Point of View: Rocio Garcia-Carbonero, MD

The invited discussant of the FIRSTMAPP study, Rocio Garcia-Carbonero, MD, of Hospital Universitario 12 de Octubre, Madrid, emphasized that pheochromocytoma and paraganglioma are rare tumors, and once they become metastatic, which is even more rare, there are few treatment options. “This is very...

Neuroendocrine Tumors

Evidence for Efficacy of Sunitinib in Malignant Pheochromocytoma and Paraganglioma

Results from the phase II ­FIRSTMAPPP study support the potential use of the tyrosine kinase inhibitor sunitinib in two rare neuroendocrine malignancies—pheochromocytoma and paraganglioma. Sunitinib significantly improved the primary endpoint of progression-free survival vs placebo, according to...

neuroendocrine tumors

Dieter Hörsch, MD: For Patients With Bronchopulmonary Neuroendocrine Tumors, Lanreotide Autogel May Be Beneficial

Dieter Hörsch, MD, of Germany’s Central Clinic in Bad Berka, discusses phase III results from the SPINET trial, the largest prospective study to date of the somatostatin analog lanreotide autogel. The study suggests that this agent may prove to be an appropriate treatment option for patients with somatostatin receptor–positive bronchopulmonary neuroendocrine tumors, especially typical carcinoids (Abstract 1096O).

Neuroendocrine Tumors

Second Primary Cancers in Patients With Neuroendocrine Tumors

In a population-based study reported in a research letter in JAMA Oncology, Bateni et al found that 8% of patients with neuroendocrine tumors (NETs) developed second primary cancers over approximately 7.5 years of follow-up, with types of secondary malignancies differing according to NET type. The...

Neuroendocrine Tumors

Study Examines Efficacy of Sunitinib in Malignant Pheochromocytoma and Paraganglioma

The first randomized study in patients with malignant pheochromocytoma and paraganglioma has found that sunitinib prolongs progression-free survival by more than 5 months. The late-breaking results of the FIRSTMAPPP trial were presented by Eric Baudin, MD, PhD, and colleagues at the European...

Neuroendocrine Tumors

Study Examines Cancer-Specific Mortality Among Patients With Neuroendocrine Tumors

In a new study published by Hallet et al in JNCCN—Journal of the National Comprehensive Cancer Network, among patients with neuroendocrine tumors (NETs), the risk of dying of cancer was higher than that of dying of other causes, but mortality varied by primary tumor site. According to the authors,...

Neuroendocrine Tumors

Neuroendocrine Tumor Specialist Pamela Kunz, MD, Looks to Promote Equity in the Workforce

In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Pamela Kunz, MD, Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center. Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine...

Kidney Cancer
CNS Cancers
Neuroendocrine Tumors

FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease

On August 13, the U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg), a hypoxia-inducible factor inhibitor, for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or...

Gastrointestinal Cancer
Pancreatic Cancer
Neuroendocrine Tumors

Lenvatinib for Previously Treated Advanced Pancreatic and Gastrointestinal Neuroendocrine Tumors

In a phase II trial (TALENT; GETNE1509) reported in the Journal of Clinical Oncology, Jaume Capdevila, MD, and colleagues found that lenvatinib produced durable responses in patients with previously treated advanced grade 1 or 2 gastroenteropancreatic neuroendocrine tumors. Study Details In the...

neuroendocrine tumors

Rocio Garcia-Carbonero, MD, on Treating Neuroendocrine Tumors of Nonpancreatic Origin With Octreotide Acetate and Axitinib

Rocio Garcia-Carbonero, MD, of Hospital Universitario 12 De Octubre, discusses results of the phase II/III AXINET trial, which showed that axitinib plus long-acting release octreotide improved overall response compared with placebo and octreotide in patients with advanced grade 1 or 2 extrapancreatic neuroendocrine tumors. However, no significant improvement in progression-free survival was observed (Abstract 360).

Neuroendocrine Tumors

Surufatinib in Advanced Pancreatic Neuroendocrine Tumors

As reported in The Lancet Oncology by Xu et al, the Chinese phase III SANET-p trial has shown significantly improved progression-free survival with surufatinib vs placebo in patients with advanced pancreatic neuroendocrine tumors. Surufatinib is a novel small-molecule inhibitor that targets...

Neuroendocrine Tumors

Novel Small-Molecule Inhibitor Surufatinib for Advanced Extrapancreatic Neuroendocrine Tumors

In the Chinese phase III SANET-ep trial reported in The Lancet Oncology, Xu et al found that surufatinib improved progression-free survival vs placebo in patients with advanced extrapancreatic neuroendocrine tumors. Surufatinib is a novel small-molecule inhibitor that targets VEGFR-1, VEGFR-2,...

Pancreatic Cancer
Neuroendocrine Tumors

Research Provides Genetic, Immune-Related Information on Pancreatic Neuroendocrine Tumors

Scientists have used artificial intelligence in an extensive analysis of the immune and genetic landscapes of pancreatic neuroendocrine tumors. Their findings were published by Young et al in the journal Gut. Pancreatic neuroendocrine cancer starts in cells that produce hormones such as insulin....

Neuroendocrine Tumors

Characteristics of Neuroendocrine Carcinomas of the Gallbladder

In a Korean study reported in the American Journal of Surgical Pathology, Lee et al identified clinicopathologic and immunohistochemical characteristics of neuroendocrine carcinomas of the gallbladder. Study Details The study involved data from 34 patients with gallbladder neuroendocrine carcinomas ...

Neuroendocrine Tumors

Impact of Chromogranin A Expression on Disease Characteristics and Prognosis in Rectal Neuroendocrine Tumors

In a single-institution Korean study reported in the American Journal of Surgical Pathology, Kim et al found that chromogranin A expression in rectal neuroendocrine tumors is associated with more aggressive clinical characteristics and poorer prognosis. As stated by the investigators, “Although...

Neuroendocrine Tumors

Update on Detecting and Treating Biologically Diverse Neuroendocrine Tumors

Neuroendocrine tumors are rare malignancies that arise in neuroendocrine cells, which can occur throughout the body but are most commonly found in the gastrointestinal tract, lungs, and pancreas. Although most neuroendocrine tumors are indolent and take years to grow, some are aggressive and grow...

Neuroendocrine Tumors

Collaborative Guideline for the Diagnosis and Management of Lung Neuroendocrine Tumors

As reported in the Journal of Thoracic Oncology by Simron Singh, MD, MPH, and colleagues, the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) have collaborated to produce a best practice guideline for the diagnosis and...

Neuroendocrine Tumors
Immunotherapy

Two Studies Focus on Emerging Treatment Options for Patients With Neuroendocrine Tumors

Two new studies led by Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park Comprehensive Cancer Center, and published in Oncotarget and Cancer, respectively, highlight possible new treatment options for patients with neuroendocrine tumors. SurVaxM The first report,...

Neuroendocrine Tumors

Novel Radiopharmaceutical May Aid in Imaging for Patients With Neuroendocrine Tumors and Liver Metastases

For patients with neuroendocrine tumors and liver metastases, a new radiopharmaceutical, Ga-68 DOTA-JR11, has shown a benefit in imaging for tumor detection, staging, and restaging, providing important information to guide treatment. In a head-to-head comparison of two somatostatin receptor (SSTR)...

Neuroendocrine Tumors

Novel Radiopharmaceutical May Aid in Imaging for Patients With Neuroendocrine Tumors and Liver Metastases

For patients with neuroendocrine tumors and liver metastases, a new radiopharmaceutical, Ga-68 DOTA-JR11, has shown a benefit in imaging for tumor detection, staging, and restaging, providing important information to guide treatment. In a head-to-head comparison of two somatostatin receptor (SSTR)...

Kidney Cancer
Neuroendocrine Tumors
Issues in Oncology
Lung Cancer
Breast Cancer

Selected Poster Presentations on Cancer Therapeutics and More

Although the live 2020 National Comprehensive Cancer Network (NCCN) Annual Conference was canceled, more than 100 posters scheduled for presentation are now available online, as part of the NCCN 2020 Virtual Annual Conference. The ASCO Post has summarized some of the clinical trial updates we found ...

Neuroendocrine Tumors
Issues in Oncology

Issues With Travel Faced by Patients Undergoing Lu-177 Dotatate Radiation Therapy

A team of researchers and patient advocates have addressed the challenges related to traveling after receiving radiation therapy involving Lu-177 dotatate in a study published by Kendi et al in The Journal of Nuclear Medicine. Due to the residual radiation activity of Lu-177 dotatate, some patients ...

Leukemia
Pancreatic Cancer
Neuroendocrine Tumors
Lung Cancer
Gynecologic Cancers
Lymphoma

FDA Pipeline: Priority Review in AML, Fast Track Designations for Pancreatic Cancer and Neuroendocrine Tumors

Over the past 2 weeks, the U.S. Food and Drug Administration (FDA) granted Priority Review to a treatment for acute myeloid leukemia (AML); Fast Track designations for agents in pancreatic cancer and pancreatic/nonpancreatic neuroendocrine tumors; approvals for companion diagnostic tests;...

Advertisement

Advertisement

Advertisement